Comparison of treatment outcomes for superficial digital flexor tendonitis in National Hunt racehorses

Witte, Stefan; Dedman, Cloe; Harriss, F.; Kelly, G.; Chang, Yu‐Mei; Witte, Thomas

doi:10.1016/j.tvjl.2016.08.003

Cited by 23 publications

(18 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, Equitend ® -treated horses returned to their pre-injury performance level whereas placebo-treated horses did not ( Table 5 ). In the placebo group the median number of races before treatment was 14 (interquartile [ 10 – 16 ]) whereas 24 months after injection it was 6 (interquartile [4.5–9.5], p = 0.0446). In the Equitend ® -treated group, values before treatment were 15 [interquartile: 7.5–25] and became 15.5 after 24 months of treatment (interquartile [10–22.5], p = 0.6382).…”

Section: Resultsmentioning

confidence: 99%

“…Tendon injury remains a frequent condition in sport and race horses [ 1 , 2 ], responsible for substantial wastage in the equine sports industry [ 3 , 4 ], and justifying continuous development of research into new treatments. In the last decade, studies substantially focused on “biological therapies”, such as glycosaminoglycan polysulphate [ 5 , 6 ], hyaluronic acid (HA) [ 5 , 7 ], platelet rich plasma (PRP) [ 8 – 10 ], insulin-like growth factor-I [ 11 ], several sources of stems cells [ 12 – 17 ]. ReGeneraTing Agents (RGTA ® ) used in the present study belong to these “biological” or “nature mimicking” therapies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Randomized controlled trial demonstrates the benefit of RGTA® based matrix therapy to treat tendinopathies in racing horses

Jacquet-Guibon

Dupays²,

Coudry

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

A randomized controlled trial was performed on racing horses, to evaluate the efficacy of a new class of therapeutic agents in regenerative medicine—ReGeneraTing Agents® (RGTA®), to treat tendinopathies. Preliminary uncontrolled studies on tendon healing in racing horses with RGTA® (OTR4131)—Equitend® showed encouraging results, justifying performing a randomized, controlled, multicenter study with a two-year racing performance follow up. The objective of this study was to evaluate the effect of Equitend® versus placebo on acute superficial digital flexor tendonitis in racing French Standardbred Trotters (ST). Twenty-two ST were randomly and blindly assigned to receive with a ratio of 2 to 1, a single Equitend® (n = 14) or placebo (n = 8) intralesional injection under ultrasonographic guidance. Horses were evaluated over 4 months, by clinical and ultrasonographic evaluations (day 0, months 1, 2, 4), and their racing performances followed up over the 2 years after treatment. During the first month of treatment, a significant decrease in the cross-sectional area (CSA) was found in the Equitend® group (p = 0.04). After 4 months, the number of Equitend® treated horses with an improved CSA was significantly higher than the placebo-treated horses (p = 0.03571). The Equitend® group returned to their pre-injury performance level, racing in, and winning, significantly more races than the placebo group (p = 0.01399 and 0.0421, respectively). Furthermore, recurrence was significantly higher in the placebo group than in the Equitend® group (71.4% vs 16.6%, p = 0.02442). In conclusion, we measured a significant, short-term, reduction effect on CSA and demonstrated a long-term beneficial effect of intralesional injection of Equitend® for the treatment of superficial digital flexor tendonitis on racing ST, racing 2. 3 times more often than placebo, with 3.3 times fewer recurrences maintaining pre-injury performance level. This study may open the way for the development of a human treatment of tendonitis.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Randomized controlled trial demonstrates the benefit of RGTA® based matrix therapy to treat tendinopathies in racing horses

Jacquet-Guibon

Dupays²,

Coudry

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…These include chronic skin ulcers (Martínez-Zapata et al, 2009), articular cartilage damage (Dold et al, 2014), bone and tendon lesions (Alsousou et al, 2009; Intini, 2009), peripheral nerve wound (Zheng et al, 2014), cardiac muscle injury (Vu et al, 2015), plastic and maxillofacial applications (Marx et al, 1998; Martínez-Zapata et al, 2009). PRP has also been used for the treatment of injuries in professional sportspersons (Taylor et al, 2011; Dold et al, 2014) and in racing animals (Waselau et al, 2008; Witte et al, 2016). The use of PRP or other platelet-derived components relies on the reactivation of latent endogenous regeneration mechanisms.…”

Section: Endogenous Regenerationmentioning

confidence: 99%

Learning from Mother Nature: Innovative Tools to Boost Endogenous Repair of Critical or Difficult-to-Heal Large Tissue Defects

Cancedda

Descalzi

Mastrogiacomo

et al. 2017

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

For repair of chronic or difficult-to-heal tissue lesions and defects, major constraints exist to a broad application of cell therapy and tissue engineering approaches, i.e., transplantation of “ex vivo” expanded autologous stem/progenitor cells, alone or associated with carrier biomaterials. To enable a large number of patients to benefit, new strategies should be considered. One of the main goals of contemporary regenerative medicine is to develop new regenerative therapies, inspired from Mother Nature. In all injured tissues, when platelets are activated by tissue contact, their released factors promote innate immune cell migration to the wound site. Platelet-derived factors and factors secreted by migrating immune cells create an inflammatory microenvironment, in turn, causing the activation of angiogenesis and vasculogenesis processes. Eventually, repair or regeneration of the injured tissue occurs via paracrine signals activating, mobilizing or recruiting to the wound site cells with healing potential, such as stem cells, progenitors, or undifferentiated cells derived from the reprogramming of tissue differentiated cells. This review, largely based on our studies, discusses the identification of new tools, inspired by cellular and molecular mechanisms overseeing physiological tissue healing, that could reactivate dormant endogenous regeneration mechanisms lost during evolution and ontogenesis.

show abstract

“…Superficial digital flexor (SDF) tendonitis is a common injury in Thoroughbred racehorses that requires prolonged rehabilitation and has unpredictable outcomes with a high incidence of re‐injury. In this study Stefan Witte and colleagues based in Switzerland, Ireland and the UK compared race outcomes after common treatments for tendon healing in National Hunt (NH) racehorses .…”

Section: Outcomes For Superficial Digital Flexor Tendonitismentioning

confidence: 99%

Highlights of recent clinically relevant papers

Wright¹

2016

Equine Veterinary Education

View full text Add to dashboard Cite

Comparison of treatment outcomes for superficial digital flexor tendonitis in National Hunt racehorses

Cited by 23 publications

References 33 publications

Randomized controlled trial demonstrates the benefit of RGTA® based matrix therapy to treat tendinopathies in racing horses

Randomized controlled trial demonstrates the benefit of RGTA® based matrix therapy to treat tendinopathies in racing horses

Learning from Mother Nature: Innovative Tools to Boost Endogenous Repair of Critical or Difficult-to-Heal Large Tissue Defects

Highlights of recent clinically relevant papers

Contact Info

Product

Resources

About